NRSNW
NeuroSense Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.05
−8.16%Price chart
Aug 3Aug 13Aug 18Aug 25Aug 31Sep 3Sep 14Sep 18
Key dataSep 18, 2026
Open$0.05
From 52W high−94.94%
Volume5091.00
Market cap$1.14M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.05
From 52W high
−94.94%
Volume
5091.00
Market cap
$1.14M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
44.9
MomentumView details →
1D Return
−8.16%
YTD Return
−85.16%
Similar companies
Latest newsMore news →
NeuroSense Therapeutics announced a redesigned, capital-efficient development strategy for its ALS drug PrimeC, including an AI-enabled formulation characterization, a comparative study against edaravone, and an optimized Phase 3 PARAGON trial design, with a New Drug Submission to Health Canada targeted for December 2026.17d agoNeuroSense Therapeutics completed the pre-NDS process with Health Canada for its ALS drug PrimeC, receiving final meeting minutes that align on the planned submission content and structure, and is advancing toward a December 2026 filing.45d agoNeuroSense Therapeutics achieved the primary endpoint in a Phase 2b ALS study with PrimeC, showing statistically significant reduction of TDP-43.83d ago